Clinical Phase II Study of Pegylated Liposomal Doxorubicin as Second-Line Treatment in Disseminated Melanoma

Publisher： Karger

E-ISSN： 2296-5262|27|6|540-544

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.27, Iss.6, 2004-12, pp. : 540-544

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure

By  

Oncology Research and Treatment, Vol. 27, Iss. 5, 2004-10 ,pp. : 441-446

Karger

Access to resources Recommend Favorite

Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 32, Iss. 1-2, 2009-01 ,pp. : 18-24

Karger

Access to resources Recommend Favorite

Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 210-214

Karger

Access to resources Recommend Favorite

Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients

By  

Oncology, Vol. 67, Iss. 3-4, 2004-11 ,pp. : 243-249

Karger

Access to resources Recommend Favorite

Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study

By  

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, Vol. 94, Iss. 7, 2015-07 ,pp. : 776-780

John Wiley & Sons Inc

Access to resources Recommend Favorite